JPMorgan analyst Anupam Rama raised the firm’s price target on Olema Oncology to $25 from $19 and keeps an Overweight rating on the shares. The analyst updated biotechnology models following the ESMO presentations.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on OLMA:
- Olema Oncology price target raised to $22 from $16 at Canaccord
- Olema Oncology breast cancer data a ‘home run,’ says H.C. Wainwright
- Olema Oncology: Median PFS was 4.6 months in Phase 2 palazestrant study
- Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant
- Olema Oncology appoints Garland to board of directors
